Feature Stories: CDC Solutions to Combat Antibiotic Resistance
CDC is a leader in the fight against antibiotic resistance. Through its AR Solutions Initiative, CDC works with partners to drive aggressive action and empower the nation to respond to this global threat. stories to learn about CDC’s work in the field with partners across the world.
AR Investments at Work: Protecting Patients and Healthcare Personnel from COVID-19
CDC is investing in partner initiatives for infection prevention and control practices in hospitals, long-term acute care facilities, and nursing homes. Read how these investments are proving to be integral in reducing the spread of antibiotic-resistant germs, and, most recently, the virus that causes COVID-19 within healthcare facilities.
CDC & AR experts discuss addressing AR after COVID-19
For CDC’s first AMR Exchange of the year, CDC met with leading antibiotic resistance experts to discuss their visions for addressing this threat post-pandemic. Read about their experiences and lessons learned, underscoring the importance of resilient health systems.
CDC Partners Estimate Healthcare Cost of Antibiotic-resistant Infections
CDC and the University of Utah School of Medicine conducted one of the largest studies on healthcare costs to treat six of the 18 most alarming antibiotic resistance threats. Cost estimates can help guide actions needed to prevent resistant infections. Read how much resistance threats contribute to healthcare costs annually.
Exploring New Approaches to Diagnose Clostridiodes difficile Infections
CDC and Henderson Lab assessed fecal metabolomes (amounts of all chemicals in feces) from patients tested for C. difficile infections. Read how this work will help to better understand what is happening in the body and what causes C. difficile.
Tailoring Antibiotic Treatment for Patients with Cystic Fibrosis
Through a project with CDC, Brown Lab developed new approaches to study the lung microbiomes of patients with cystic fibrosis (CF), who often get chronic infections. This work will help improve antibiotic treatments for these patients. Read about tailored antibiotic treatments for CF.
CDC is Taking Global Action to Fight AR
CDC works around the world to combat antibiotic resistance (AR), which is sometimes referred to as antimicrobial resistance (AMR) outside of the United States. CDC and the U.S. government are emphasizing the importance of accelerating the fight against AR globally by calling on stakeholders to take bold actions through the AMR Challenge. Read about how CDC is taking global action to fight AR.
Tracking Antibiotic Resistance in Kenya and Senegal
As of 2018, CDC is working with experts in 28 countries with its Antibiotic Resistance (AR) Solutions Initiative to develop and pilot solutions that address the emergence and spread of AR. For example, public health experts in Kenya and Senegal are collaborating with CDC to strengthen their AR surveillance to better track and respond to AR threats. Read about how tracking antibiotic resistance in Kenya and Senegal.
CDC Core Elements to Help Resource-Limited Settings Improve Antibiotic Use
In 2018, CDC released a new Core Elements as a guide for implementing antibiotic stewardship programs in resource-limited settings that have fragile health systems and lack robust, regulatory frameworks. It provides practical, high-impact strategies to improve antibiotic use and fight antibiotic resistance. Read about the Core Elements guide.
Antibiotic Resistance: A Global Threat
Antibiotic resistance requires a collaborative approach across countries to detect, prevent, and respond to these threats. Global leaders are joining CDC’s AMR Challenge by committing to action across healthcare, food, communities, and the environment (soil and water) to accelerate the fight. Read more about CDC collaboration to support global action.
Combating Antimicrobial Resistance in Vietnam
Vietnam has made fighting antimicrobial resistance a national priority. CDC is helping Vietnam establish a national surveillance system, which will provide the framework to track, detect, and contain the spread of antimicrobial resistance in the country. The overall goal of this effort is to keep patients safe. Read about combating antimicrobial resistance in Vietnam.
Pilot Program with HP Accelerates Antibiotic Testing
In 2018, CDC and HP Inc. launched a pilot program that installed HP printers as part of CDC’s Antibiotic Resistance Laboratory Network. The inkjet printing technology, adapted for printing antibiotic susceptibility testing panels, will help clinicians decide if a new-to-market drug could effectively treat a highly drug-resistant infection. Read about the pilot program to accelerate antibiotic testing.
Stop Spread of Unusual Antibiotic Resistance
Content: Antibiotic resistance is harder to control once it spreads and becomes common. A CDC report highlighted the importance of containing the spread of “unusual” resistance and includes data from CDC’s AR Lab Network, a resource that can help identify these threats rapidly. Read about how CDC empowers states to help keep germs from spreading.
Antibiotic Resistance (AR) Lab Network Established as New Fungal Threat Emerges
CDC’s Antibiotic Resistance Laboratory Network (AR Lab Network) supports nationwide lab capacity to rapidly detect antibiotic resistance, and inform local responses to prevent spread and protect people. Read an example of the AR Lab Network’s importance and early success, highlighted in its response to the emerging resistant fungus, Candida auris. Read about the AR Lab Network and new fungal threat.
C. auris: CDC’s Response to a Global Emerging Threat
Candida auris (C. auris) is an emerging multidrug-resistant yeast. In 2016, CDC released a clinical alert asking labs and healthcare workers to be on the lookout for C. auris, and investigated reported cases with state and local public health partners. CDC continues to actively work with partners to better contain and prevent spread of C. auris. Read about CDC’s response to C. auris.
Improving Antibiotic Prescribing with Rapid Diagnostics and Education
CDC is working to help healthcare providers better diagnose Valley fever, caused by a fungus, in part by supporting development of rapid diagnostic tests. These tests can quickly provide clinicians with the information they need to appropriately treat patients. Read about improving antibiotic prescribing.
CDC and Partners Tackle Drug-Resistant TB in India
To protect Americans from threats like drug-resistant tuberculosis (TB), CDC is reinforcing international collaborations and capacities with countries worldwide. This includes improving TB infection control in key healthcare facilities; strengthening diagnostic and treatment services in the public and private sector; and increasing TB treatment adherence to reduce rates and spread. Read about tackling drug-resistant TB.
Newly Reported Gene, mcr-1, Threatens Last-Resort Antibiotics
A new gene known as mcr -1—which can make bacteria resistant a last-resort drug—was first reported in China in November 2015 and in the United States in May 2016. Read how CDC and federal partners began hunting for and tracking mcr -1 in the United States and the importance of a coordinated public health response.